Official announcements (8-K)

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn November 2, 2026, The Chemours Company (the “Company”) issued a press release regarding its third quarter 2026 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Tuesday, November 3, 2026, for its conference call scheduled for that time. The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that …

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

In the company's wordsOn September 9, 2026, The Chemours Company (“Chemours”), DuPont de Nemours, Inc. (“DuPont”), Corteva, Inc. and EIDP, Inc., a subsidiary of Corteva, Inc. (together with Corteva, Inc., “Corteva”), entered into a settlement agreement (the “Settlement Agreement”) with the State of North Carolina and 11 local entities located in the vicinity of Chemours’ Fayetteville Works facility, including Bladen County, Brunswick County, Columbus County, Cumberland County, New Hanover County, Robeson County, Sampson County, Town of Wrightsville Beach, City of Lumberton, Village of Bald Head Island and the Lower Cape Fear Water and Sewer Authority (collectively, the “Local Entities,” and …

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

In the company's wordsOn September 10, 2026, Chemours issued a press release announcing the matters described in this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The …

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

In the company's wordsOn September 9, 2026, The Chemours Company (the "Company") posted a presentation on its Investor Relations section of its website at www.investors.chemours.com. The Company will use this presentation in connection with upcoming meetings with investors, analysts and other interested parties. The presentation is furnished hereto as Exhibit 99.1. The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn August 4, 2026, The Chemours Company (the “Company”) issued a press release regarding its second quarter 2026 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Wednesday, August 5, 2026, for its conference call scheduled for that time. The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that …

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

In the company's wordsOn June 23, 2026, The Chemours Company (“Chemours”) agreed to a proposed Consent Decree with the United States Environmental Protection Agency (the “EPA”) and the West Virginia Department of Environmental Protection (the “WVDEP”) to resolve claims asserted by the EPA and the WVDEP with respect to PFAS emissions and other alleged activities at certain Chemours facilities, including the Washington Works, Fayetteville Works and Chambers Works facilities (the “Settlement”). Pursuant to the Settlement, Chemours has agreed to pay a civil penalty in the amount of $22.5 million, payable in three consecutive annual installments, beginning within 30 days of the approval of the …

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

In the company's wordsOn June 24, 2026, Chemours issued a press release announcing the matters described in this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn May 5, 2026, The Chemours Company (the “Company”) issued a press release regarding its first quarter 2026 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Wednesday, May 6, 2026, for its conference call scheduled for that time. The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

In the company's wordsThe Chemours Company (the “Company”) held its annual meeting of shareholders on April 24, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders, upon the recommendation of the Company’s Board of Directors, approved The Chemours Company 2026 Equity and Incentive Plan (the “Plan”). The Plan provides for grants to employees, independent contractors, or non-employee directors of the Company of different forms of awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards and dividend equivalent rights, with a maximum of 6,375,275 shares reserved for issuance, less one share for …

Shared shareholder vote results (Item 5.07)

How shareholders voted on board members and proposals.

In the company's wordsThe Company held its Annual Meeting on April 24, 2026. At the Annual Meeting, shareholders: •elected all eleven director nominees to serve a one-year term; •approved the Company’s annual “say-on-pay” vote on an advisory basis; •approved the Plan; and •ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm. The final voting results for each proposal were as follows: Proposal 1 – Election of Directors to Serve One-Year Term Nominee For Against Abstain Broker Non-Votes George R. Brokaw 108,084,939 (95.8%) 4,608,412 122,192 16,493,566 Alister Cowan 111,973,151 (99.3%) 721,042 121,349 16,493,567 Mary B. Cranston …

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

In the company's wordsEntry into a Material Definitive Agreement. The information set forth in Item 8.01 of this Current Report on Form 8-K regarding the 2020 Base Indenture (as defined below) and the 2026 Fourth Supplemental Indenture (as defined below) is incorporated herein by reference.

Took on a major new debt or obligation (Item 2.03)

New borrowing adds to what the company owes and the interest it pays.

In the company's wordsThe information set forth in Item 8.01 of this Current Report on Form 8-K regarding the Notes is incorporated herein by reference.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

In the company's wordsOn March 12, 2026, The Chemours Company (the “Company”) closed the private offering (the “Offering”) of $700,000,000 aggregate principal amount of the Company’s 7.875% Senior Notes due 2034 (the “Notes”), pursuant to the Purchase Agreement (the “Purchase Agreement”), dated as of February 26, 2026, by and among the Company, the guarantor named therein and Goldman Sachs & Co. LLC, as representative of the several initial purchasers named therein. The Notes were issued pursuant to the Indenture, dated as of November 27, 2020 (the “2020 Base Indenture”), between the Company and Deutsche Bank Trust Company Americas, as successor trustee to U.S. Bank Trust Company, National …

Announced another event (Item 8.01)

Another event the company chose to report publicly.

In the company's wordsOn February 26, 2026, The Chemours Company issued press releases announcing the launch and pricing of its offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of notes. A copy of the foregoing press releases are attached hereto as Exhibits 99.1 and 99.2 and are incorporated into this Item 8.01 by reference.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn February 19, 2026, The Chemours Company (the “Company”) issued a press release regarding its fourth quarter and full year 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. The Company will post to its investor relations website, investors.chemours.com, an investor presentation by 8:00 a.m. Eastern Daylight Time on Friday, February 20, 2026, for its conference call scheduled for that time. The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the …

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

In the company's wordsOn January 15, 2026 (the “Effective Date”), The Chemours Company (the “Company”), through its subsidiary, The Chemours (Taiwan) Company Limited (“Seller”), entered into four separate Real Estate Sale and Purchase Agreements (collectively, the “Purchase Agreements”) with four affiliated entities: Century Wind Power Co., Ltd., Century Iron and Steel Industrial Co., Ltd., Century Huaxin Wind Energy Co., Ltd. and Mr. Lai Wen-Hsiang (collectively, the “Buyers”) to sell ten parcels of land in Kuan Yin, Taiwan (collectively, the “Property”) for a total purchase price of approximately $360 million. The Company intends to use the cash proceeds from the sale of the Property to …

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

In the company's wordsOn January 15, 2026, the Company issued a press release announcing the sale of the property. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn November 6, 2025, The Chemours Company (the “Company”) issued a press release regarding its third quarter 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. Senior management's prepared remarks are attached as Exhibit 99.2 to this report. The Company will post to its investor relations website, investors.chemours.com, an investor presentation and prepared remarks by 8:00 a.m. Eastern Daylight Time on Friday, November 7, 2025, for its conference call scheduled for that time. The information furnished with this report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

Took on a major new debt or obligation (Item 2.03)

New borrowing adds to what the company owes and the interest it pays.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

Shared shareholder vote results (Item 5.07)

How shareholders voted on board members and proposals.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

Took on a major new debt or obligation (Item 2.03)

New borrowing adds to what the company owes and the interest it pays.

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

Shared documents (Item 9.01)

Attached documents only, such as a press release.

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

Took on a major new debt or obligation (Item 2.03)

New borrowing adds to what the company owes and the interest it pays.

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

Took on a major new debt or obligation (Item 2.03)

New borrowing adds to what the company owes and the interest it pays.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Announced another event (Item 8.01)

Another event the company chose to report publicly.